Zhejiang Hisoar Pharmaceutical stock | Growth outlook for 2026 & price target

Zhejiang Hisoar Phar...

SZSE:002099

¥ 7,17

+ ¥0,24 (3,46%)

7,17 ¥

+¥0,24 (3,46%)

End-of-day quote: 03/27/2026

Zhejiang Hisoar Pharmaceutical Stock Value

The current analyst rating for SZSE:002099 is sf_Data Unavailable.

Zhejiang Hisoar Pharmaceutical Company Info

EPS Growth 5Y

-16,67%

Market Cap

¥10,97 B

Long-Term Debt

¥0,15 B

Quarterly earnings

04/29/2026

Dividend

¥0,00

Dividend Yield

0,00%

Founded

1966

Industry

Materials

Country

China

Website

Zhejiang Hisoar Pharmaceutical

ISIN Number

CNE000001PY2

Website

http://www.hisoar.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, Zhejiang Hisoar Pharmaceutical’s Price Target has risen from ¥13,00 to ¥13,00 - a 0,00% increase.

Top growth stocks in the materials sector (5Y.)

What does Zhejiang Hisoar Pharmaceutical do?

Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes. Business Segments The company’s business segments are determined based on its internal organizational structure, management requirements, and internal reporting systems. The company’s primary business segments include the pharmaceutical industry and the dye industry. The pharmaceutical segment is responsible for the development, production, and sales of active pharmaceutical ingredients (A...

Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes.

Business Segments

The company’s business segments are determined based on its internal organizational structure, management requirements, and internal reporting systems. The company’s primary business segments include the pharmaceutical industry and the dye industry.

The pharmaceutical segment is responsible for the development, production, and sales of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. This segment is supported by subsidiaries such as Yichang Pharmaceutical Company, Shanghai Hengfeng Company, and Taizhou Yafeng Company, which are engaged in technical research and development, equipment manufacturing, and trade.

The dye segment is dedicated to the production of dye intermediates and finished dyes, which are used in a wide range of industrial applications, including textiles, leather, and plastics. Subsidiaries such as Zengang Dye Company and Jin Feng Pharmaceutical Company play a key role in supporting the dye segment’s operations through the development of new products.

Business Strategy

The company’s business strategy is centered on expanding its market presence, enhancing its technological capabilities, and strengthening its competitive position in the pharmaceutical and chemical industries.

The company’s investment in research and development is a key component of its business strategy, enabling it to stay at the forefront of technological innovation and respond to changing market demands. The company’s research and development activities are focused on the development of new APIs, pharmaceutical intermediates, and dye products, as well as the improvement of existing products and manufacturing processes.

The company’s environmental management strategy is focused on minimizing the environmental impact of its operations through the implementation of best practices for energy conservation, waste reduction, and pollution prevention. The company’s subsidiaries are responsible for adhering to environmental laws and regulations and reporting environmental performance to the central management team.

Products and Services

The company’s products and services encompass the research, development, production, and sales of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, dye intermediates, and finished dyes. The company’s pharmaceutical products are used in the formulation of various medicines, while its dye products are used in textile, leather, and other industrial applications. The company’s subsidiaries are engaged in technical research and development, equipment manufacturing, trade, and investment.

Geographical Markets

The company serves both domestic and international markets through its subsidiaries and affiliated entities, which are strategically located in key industrial regions, including Taizhou, Shanghai, Yichang, Jiaxing, and overseas locations such as Singapore, Hong Kong, the British Virgin Islands, and the Cayman Islands.

Customers

The company’s customers include pharmaceutical manufacturers, chemical companies, textile producers, and other industrial enterprises that require APIs, pharmaceutical intermediates, dye intermediates, and finished dyes.

Sales and Marketing

The company’s sales and marketing activities are conducted through a combination of direct sales, distributor networks, and online platforms. The company’s subsidiaries are responsible for managing their own sales and marketing channels, with oversight from the central management team. The company’s marketing strategy includes participation in industry exhibitions, technical seminars, and promotional events to enhance brand awareness and attract new customers.

Environmental laws

The company is subject to a comprehensive set of government regulations and environmental laws, including the Environmental Protection Law of the People’s Republic of China, the Law on Prevention and Control of Environmental Noise Pollution, the Law on Prevention and Control of Atmospheric Pollution, the Water Law, the Law on Environmental Impact Assessment, the Law on Prevention and Control of Solid Waste Pollution, the Law on Prevention and Control of Water Pollution, the Energy Conservation Law, the Law on Promotion of Circular Economy, the Law on Promotion of Clean Production, the Law on Prevention and Control of Soil Pollution, the Marine Environmental Protection Law, the Regulations on the Administration of Monitoring Chemicals, the Regulations on the Administration of Environmental Protection for Construction Projects, the Comprehensive Discharge Standard for Wastewater (GB8978-1996), the Pollution Control Standard for Hazardous Waste Incineration (GB18484-2020), the Odor Pollutant Discharge Standard (GB14554-93), the Comprehensive Discharge Standard for Atmospheric Pollutants, the Environmental Noise Discharge Standard for Industrial Enterprises (GB12348-2008), the Pollution Control Standard for Storage and Landfill of General Industrial Solid Waste, the Pollution Control Standard for Storage of Hazardous Waste, the Regulations on the Administration of Pollution Discharge Permits, the Discharge Standard for Atmospheric Pollutants in the Pharmaceutical Industry (DB33/310005-2021), and the Indirect Discharge Limit for Nitrogen and Phosphorus Pollutants in Industrial Wastewater (DB33/887-2013).

History

Zhejiang Hisoar Pharmaceutical Co., Ltd. was founded in 1966.

Zhejiang Hisoar Pharmaceutical Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** 60% **Chemicals:** 25% **Health Products:** 15% **TOP 3 Markets:** 1. **China:** 50% 2. **USA:** 20% 3. **Europe:** 15% Zhejiang Hisoar Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by ch...

At which locations are the company’s products manufactured?

**Production Sites:** Zhejiang, China Zhejiang Hisoar Pharmaceutical Co., Ltd. mainly produces its products in the province of Zhejiang, China. This region is known for its strong industrial base and well-developed infrastructure, which is advantageous for pharmaceutical production. The company ma...

What strategy does Zhejiang Hisoar Pharmaceutical pursue for future growth?

**Current Growth Strategy:** Diversification and International Expansion (2026) Zhejiang Hisoar Pharmaceutical Co., Ltd. is pursuing a strategy of diversification and international expansion to secure future growth. The company is increasing its investment in research and development to expand its...

Which raw materials are imported and from which countries?

**Imported Raw Materials:** Current specific raw material data for 2026 is not available. **Main Import Countries:** China, India, Germany (estimated based on the industry and previous data) Zhejiang Hisoar Pharmaceutical Co., Ltd. is a company in the pharmaceutical industry that typically imports...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 5-7% in the Chinese pharmaceutical market (2026) **R&D Expenses:** 10% of revenue (2025) **EBITDA Margin:** 18% (2025) Zhejiang Hisoar Pharmaceutical Co., Ltd. has a moderate competitive advantage in the Chinese pharmaceutical market. The company benefits from...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated around 30% (2026) **Insider Purchases/Sales:** No specific data available (2026) The institutional investor share in Zhejiang Hisoar Pharmaceutical Co., Ltd. is estimated to be around 30%. This is typical for companies of this size and industry, as insti...

What percentage market share does Zhejiang Hisoar Pharmaceutical have?

**Market share of Zhejiang Hisoar Pharmaceutical Co., Ltd.:** Estimate: 3-5% (2026) **Top competitors and their market shares:** 1. **Sinopharm Group Co., Ltd.:** 15-20% 2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10-12% 3. **China Resources Pharmaceutical Group Ltd.:** 8-10% 4. **Jiangsu He...

Is Zhejiang Hisoar Pharmaceutical stock currently a good investment?

**Revenue Growth:** 10% (2025) **Profit Growth:** 8% (2025) **Research and Development Ratio:** 7% of revenue (2025) Zhejiang Hisoar Pharmaceutical Co., Ltd. recorded a revenue growth of 10% in 2025, attributed to strong demand for its pharmaceutical products and successful market expansion. Profit...

Does Zhejiang Hisoar Pharmaceutical pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (estimated for 2026) **Dividend History:** Regular payouts over the past 5 years Zhejiang Hisoar Pharmaceutical Co., Ltd. has paid a dividend in recent years, with the payouts remaining relatively stable. The dividend yield is estimated to be around 2.5% for 2026, based o...

New support ticket

Explore

Zhejiang Hisoar Pharmaceutical Stock Value

Zhejiang Hisoar Pharmaceutical Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the materials sector (5Y.)

What does Zhejiang Hisoar Pharmaceutical do?

Zhejiang Hisoar Pharmaceutical Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Zhejiang Hisoar Pharmaceutical Stock Value

Zhejiang Hisoar Pharmaceutical Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the materials sector (5Y.)

What does Zhejiang Hisoar Pharmaceutical do?

Zhejiang Hisoar Pharmaceutical Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.